Personalized dosing is the future of medication, moving towards treatments based on individual needs. Current dosing practices are based on average responses from limited clinical trials, overlooking variations due to gender, race, and genetics. Women are frequently excluded from this research and risk receiving dosages designed for men, which increases the chance of adverse effects.
To address this this challenge, our team is designing a minimally invasive blood test to measure therapeutic monoclonal antibodies accurately in women. This approach will optimize drug dosing by considering individual factors, enhancing treatment efficacy, minimizing side effects, and ensuring more equitable and effective care.